Bangladeshi glau­co­ma eye drop man­u­fac­tur­er banned from sup­ply­ing prod­ucts in Eu­rope

Bangladesh-based Bex­im­co Phar­ma­ceu­ti­cals has been pro­hib­it­ed from sup­ply­ing its tim­o­lol and la­tanoprost pre­scrip­tion eye drops for glau­co­ma in the EU and EEA mar­kets on the back of fa­cil­i­ty de­sign con­cerns.

The fa­cil­i­ty’s GMP cer­tifi­cate, orig­i­nal­ly is­sued in Jan­u­ary 2020, will be with­drawn. The Mal­ta Med­i­cines Au­thor­i­ty found one crit­i­cal, three ma­jor and 15 oth­er de­fi­cien­cies af­ter it con­duct­ed an in­spec­tion be­tween Ju­ly 28 and Aug. 1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA